PharmaCyte Biotech, Inc. (PMCB) · Oct 16, 2026 · Auditor change

PharmaCyte auditor change leaves internal-control weaknesses unresolved

Auditor change — CBIZ replaced by Grassi; no disagreements reported

PharmaCyte changed auditors for fiscal 2027, reporting no accounting dispute—but material weaknesses in financial controls remain the key signal.

PharmaCyte remains an early-stage biotech trying to advance its Cell-in-a-Box cancer-therapy platform toward a pancreatic-cancer trial, with no approved products or revenue and an FDA clinical hold that has remained unresolved since 2020. Against that backdrop, this filing is administrative rather than a clinical or financing catalyst.

The auditor switch does not indicate a reported accounting fight. The Audit Committee dismissed CBIZ CPAs and engaged Grassi for fiscal 2027, but the filing says CBIZ’s prior audit reports were not adverse, disclaimed, qualified, or modified. 〔0〕

The more important signal is that known control weaknesses remain in the story. PharmaCyte disclosed no disagreements or reportable events other than weaknesses involving insufficient segregation of duties and insufficient management review controls. That makes the change mildly concerning from a reporting-process standpoint, but not evidence in this filing of a restatement, audit qualification, or accounting-policy dispute.

It barely changes the core business situation. Grassi’s first review will cover the quarter ending October 31, 2026, but the filing adds no update on the FDA hold, clinical progress, funding, or the underlying therapy program. The company’s latest quarterly filing still described the development program as delayed by the hold and related strategic issues.

Bottom line: This is a governance and reporting-process change, not a development breakthrough or setback. The absence of an audit dispute is reassuring, but the unresolved internal-control weaknesses keep the signal mixed and modest in importance.

What to watch next

Grassi’s first interim review for the quarter ending October 31, 2026

Original filing on SEC EDGAR

More PharmaCyte Biotech, Inc. news

PharmaCyte auditor change leaves internal-control weaknesses unresolved | PMCB Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.